CDK1 and neoplasm: Selective inhibition of CDK1/2 and the core component BUD31 of restriction enzymes can induce apoptosis of TNBC tumor cells overexpressing MYC, suggesting that TNBC, especially the BL1 and M subtypes, might benefit from CDK1/2 and restriction enzyme inhibitor treatment.